Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions

Bibliography

• LEE WM: Drug-induced hepatotoxicity. N. Engl. J. Med. (2003) 349(5):474-485.
   PubMed Web of Science ®Google Scholar
• KAPLOWITZ N: Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. (2005) 4(6):489-499.
   PubMed Web of Science ®Google Scholar
• YANG Y, BLOMME EA, WARING JF: Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem. Biol. Interact. (2004) 150(1):71-85.
   PubMed Web of Science ®Google Scholar
• WARING JF, HALBERT DN: The promise of toxicogenomics. Curr. Opin. Mol. Ther. (2002) 4(3):229-235.
   PubMed Web of Science ®Google Scholar
• WALGREN JL, MITCHELL MD, THOMPSON DC: Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. (2005) 35(4):325-361.
   PubMed Web of Science ®Google Scholar
• GALE EA: Lessons from the glitazones: a story of drug development. Lancet (2001) 357(9271):1870-1875.
   PubMed Web of Science ®Google Scholar
• KAWAI K, KAWASAKI-TOKUI Y, ODAKA T et al.: Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung (1997) 47(4):356-368.
   PubMed Web of Science ®Google Scholar
• LOI CM, ALVEY CW, RANDINITIS EJ et al.: Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J. Clin. Pharmacol. (1997) 37(11):1038-1047.
   PubMed Web of Science ®Google Scholar
• HE K, TALAAT RE, POOL WF et al.: Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab. Dispos. (2004) 32(6):639-646.
   PubMed Web of Science ®Google Scholar
• HONMA W, SHIMADA M, SASANO H et al.: Phenol sulfotransferase, ST-1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab. Dispos. (2002) 30(8):944-949.
   PubMed Web of Science ®Google Scholar
• KASSAHUN K, PEARSON PG, TANG W et al.: Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. (2001) 14(1):62-70.
   PubMed Web of Science ®Google Scholar
• RAMACHANDRAN V, KOSTRUBSKY VE, KOMOROSKI BJ et al.: Troglitazone increases cytochrome P450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab. Dispos. (1999) 27(10):1194-1199.
   PubMed Web of Science ®Google Scholar
• SMITH KS, SMITH PL, HEADY TN et al.: In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem. Res. Toxicol. (2003) 16(2):123-128.
   PubMed Web of Science ®Google Scholar
• JU C: Immunological mechanisms of drug-induced liver injury. Curr. Opin. Drug Discov. Devel. (2005) 8(1):38-43.
   PubMed Web of Science ®Google Scholar
• ROBIN MA, LE ROY M, DESCATOIRE V, PESSAYRE D: Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J. Hepatol. (1997) 26(Suppl. 1):23-30.
   PubMedGoogle Scholar
• LIU ZX, KAPLOWITZ N: Immune-mediated drug-induced liver disease. Clin. Liver Dis. (2002) 6(3):755-774.
   PubMedGoogle Scholar
• JAESCHKE H, GORES GJ, CEDERBAUM AI et al.: Mechanisms of hepatotoxicity. Toxicol. Sci. (2002) 65(2):166-176.
   PubMed Web of Science ®Google Scholar
• GREAVES RR, AGARWAL A, PATCH D et al.: Inadvertent diclofenac rechallenge from generic and non-generic prescribing, leading to liver transplantation for fulminant liver failure. Eur. J. Gastroenterol. Hepatol. (2001) 13(1):71-73.
   PubMed Web of Science ®Google Scholar
• NAVARRO VJ, SENIOR JR: Drug-related hepatotoxicity. N. Engl. J. Med. (2006) 354(7):731-739.
   PubMed Web of Science ®Google Scholar
• VIDELA LA, FERNANDEZ V, TAPIA G, VARELA P: Oxidative stress-mediated hepatotoxicity of iron and copper: role of Kupffer cells. Biometals (2003) 16(1):103-111.
   PubMed Web of Science ®Google Scholar
• MANIRATANACHOTE R, SHIBATA A, KANEKO S et al.: Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. Toxicology (2005) 216(1):15-23.
   PubMed Web of Science ®Google Scholar
• OBERMAYER-STRAUB P, STRASSBURG CP, MANNS MP: Autoimmune hepatitis. J. Hepatol. (2000) 32(Suppl. 1):181-197.
   PubMed Web of Science ®Google Scholar
• OBERMAYER-STRAUB P, STRASSBURG CP, MANNS MP: Target proteins in human autoimmunity: cytochromes P450 and UDP- glucuronosyltransferases. Can. J. Gastroenterol. (2000) 14(5):429-439.
   PubMed Web of Science ®Google Scholar
• AITHAL GP, RAMSAY L, DALY AK et al.: Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology (2004) 39(5):1430-1440.
   PubMed Web of Science ®Google Scholar
• JU C, POHL LR: Tolerogenic role of Kupffer cells in immune-mediated adverse drug reactions. Toxicology (2005) 209(2):109-112.
   PubMed Web of Science ®Google Scholar
• NJOKU DB, MELLERSON JL, TALOR MV et al.: Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis. Clin. Vaccine Immunol. (2006) 13(2):258-265.
   PubMed Web of Science ®Google Scholar
• PARK BK, NAISBITT DJ, GORDON SF, KITTERINGHAM NR, PIRMOHAMED M: Metabolic activation in drug allergies. Toxicology (2001) 158(1-2):11-23.
   PubMed Web of Science ®Google Scholar
• SHEU SS, NAUDURI D, ANDERS MW: Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim. Biophys. Acta (2006) 1762(2):256-265.
   PubMed Web of Science ®Google Scholar
• GOMEZ-LECHON MJ, PONSODA X, BORT R, CASTELL JV: The use of cultured hepatocytes to investigate the metabolism of drugs and mechanisms of drug hepatotoxicity. Altern Lab. Anim. (2001) 29(3):225-231.
   PubMed Web of Science ®Google Scholar
• NISSINEN E, KAHEINEN P, PENTTILA KE, KAIVOLA J, LINDEN IB: Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson’s disease, does not impair mitochondrial energy production. Eur. J. Pharmacol. (1997) 340(2-3):287-294.
   PubMed Web of Science ®Google Scholar
• HAASIO K, NISSINEN E, SOPANEN L, HEINONEN EH: Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects. J. Neural Transm. (2002) 109(11):1391-1401.
   PubMed Web of Science ®Google Scholar
• ULRICH RG, BACON JA, BRASS EP et al.: Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. Chem. Biol. Interact. (2001) 134(3):251-270.
   PubMed Web of Science ®Google Scholar
• MASUBUCHI Y, NAKAYAMA S, HORIE T: Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology (2002) 35(3):544-551.
   PubMed Web of Science ®Google Scholar
• NEBERT DW, INGELMAN-SUNDBERG M, DALY AK: Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab. Rev. (1999) 31(2):467-487.
   PubMed Web of Science ®Google Scholar
• AITHAL GP, DAY CP, LEATHART JB, DALY AK: Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics (2000) 10(6):511-518.
   PubMedGoogle Scholar
• ACUNA G, FOERNZLER D, LEONG D et al.: Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J. (2002) 2(5):327-334.
   PubMedGoogle Scholar
• WATANABE I, TOMITA A, SHIMIZU M et al.: A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with Type 2 diabetes mellitus. Clin. Pharmacol. Ther. (2003) 73(5):435-455.
   PubMed Web of Science ®Google Scholar
• YOSHIGAE Y, KONNO K, TAKASAKI W, IKEDA T: Characterization of UDP-glucuronosyltransferases (UGTs) involved in the metabolism of troglitazone in rats and humans. J. Toxicol. Sci. (2000) 25(5):433-441.
   PubMedGoogle Scholar
• GANEY PE, LUYENDYK JP, MADDOX JF, ROTH RA: Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem. Biol. Interact. (2004) 150(1):35-51.
   PubMed Web of Science ®Google Scholar
• ROTH RA, LUYENDYK JP, MADDOX JF, GANEY PE: Inflammation and drug idiosyncrasy-is there a connection? J. Pharmacol. Exp. Ther. (2003) 307(1):1-8.
   PubMed Web of Science ®Google Scholar
• YEE SB, KINSER S, HILL DA et al.: Synergistic hepatotoxicity from coexposure to bacterial endotoxin and the pyrrolizidine alkaloid monocrotaline. Toxicol. Appl. Pharmacol. (2000) 166(3):173-185.
   PubMed Web of Science ®Google Scholar
• LUYENDYK JP, SHORES KC, GANEY PE, ROTH RA: Bacterial lipopolysaccharide exposure alters aflatoxin B(1) hepatotoxicity: benchmark dose analysis for markers of liver injury. Toxicol. Sci. (2002) 68(1):220-225.
   PubMed Web of Science ®Google Scholar
• SU GL, KLEIN RD, AMINLARI A et al.: Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4. Hepatology (2000) 31(4):932-936.
   PubMed Web of Science ®Google Scholar
• SU GL, GONG KQ, FAN MH et al.: Lipopolysaccharide-binding protein modulates acetaminophen-induced liver injury in mice. Hepatology (2005) 41(1):187-195.
   PubMed Web of Science ®Google Scholar
• LUYENDYK JP, MADDOX JF, COSMA GN et al.: Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J. Pharmacol. Exp. Ther. (2003) 307(1):9-16.
   PubMed Web of Science ®Google Scholar
• BUCHWEITZ JP, GANEY PE, BURSIAN SJ, ROTH RA: Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J. Pharmacol. Exp. Ther. (2002) 300(2):460-467.
   PubMed Web of Science ®Google Scholar
• SHENTON JM, POPOVIC M, CHEN J, MASSON MJ, UETRECHT JP: Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown–Norway rat. Chem. Res. Toxicol. (2005) 18(12):1799-1813.
   PubMed Web of Science ®Google Scholar
• SHENTON JM, TERANISHI M, ABU-ASAB MS, YAGER JA, UETRECHT JP: Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem. Res. Toxicol. (2003) 16(9):1078-1089.
   PubMed Web of Science ®Google Scholar
• SEGUIN B, BOUTROS PC, LI X, OKEY AB, UETRECHT JP: Gene expression profiling in a model of d-penicillamine-induced autoimmunity in the Brown–Norway rat: predictive value of early signs of danger. Chem. Res. Toxicol. (2005) 18(8):1193-1202.
   PubMed Web of Science ®Google Scholar
• BOURDI M, MASUBUCHI Y, REILLY TP et al.: Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology (2002) 35(2):289-298.
   PubMed Web of Science ®Google Scholar
• DENG X, STACHLEWITZ RF, LIGUORI MJ et al.: Modest inflammation enhances diclofenac hepatotoxicity in rats: a potential animal model of idiosyncratic drug reaction. Society of Toxicology 2006 Annual Meeting. Toxicol. Sci. (2006) 90(1):Abstract 1711.
   Google Scholar
• ROTH RA, HARKEMA JR, PESTKA JP, GANEY PE: Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents? Toxicol. Appl. Pharmacol. (1997) 147(2):300-311.
   PubMed Web of Science ®Google Scholar
• VIAL T, GOUBIER C, BERGERET A et al.: Side effects of ranitidine. Drug Saf. (1991) 6(2):94-117.
   PubMed Web of Science ®Google Scholar
• LUYENDYK JP, MATTES WB, BURGOON LD et al.: Gene expression analysis points to hemostasis in livers of rats cotreated with lipopolysaccharide and ranitidine. Toxicol. Sci. (2004) 80(1):203-213.
   PubMed Web of Science ®Google Scholar
• LUYENDYK JP, SHAW PJ, GREEN CD et al.: Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J. Pharmacol. Exp. Ther. (2005) 314(3):1023-1031.
   PubMed Web of Science ®Google Scholar
• LUYENDYK JP, LEHMAN-MCKEEMAN LD, NELSON DM et al.: Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine. J. Pharmacol. Exp. Ther. (2006) 317(2):635-643.
   PubMed Web of Science ®Google Scholar
• LUYENDYK JP, LEHMAN-MCKEEMAN LD, NELSON DM et al.: Unique gene expression and hepatocellular injury in the lipopolysaccharide-ranitidine drug idiosyncrasy rat model: comparison with famotidine. Toxicol. Sci. (2006) 90(2):569-585.
   PubMed Web of Science ®Google Scholar
• MADDOX JF, LUYENDYK JP, COSMA GN et al.: Metabonomic evaluation of idiosyncrasy-like liver injury in rats cotreated with ranitidine and lipopolysaccharide. Toxicol. Appl. Pharmacol. (2006) 212(1):35-44.
   PubMed Web of Science ®Google Scholar
• WARING JF, LIGUORI MJ, LUYENDYK JP et al.: Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J. Pharmacol. Exp. Ther. (2006) 316(3):1080-1087.
   PubMed Web of Science ®Google Scholar
• BERTINO J Jr, FISH D: The safety profile of the fluoroquinolones. Clin. Ther. (2000) 22(7):798-817; discussion 797.
   PubMed Web of Science ®Google Scholar
• LIGUORI MJ, ANDERSON LM, BUKOFZER S et al.: Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology (2005) 41(1):177-186.
   PubMed Web of Science ®Google Scholar
• JAESCHKE H, SMITH CW, CLEMENS MG, GANEY PE, ROTH RA: Mechanisms of inflammatory liver injury: adhesion molecules and cytotoxicity of neutrophils. Toxicol. Appl. Pharmacol. (1996) 139(2):213-226.
   PubMed Web of Science ®Google Scholar
• ABDULLA D, GORALSKI KB, RENTON KW: The regulation of cytochrome P450 2E1 during LPS-induced inflammation in the rat. Toxicol. Appl. Pharmacol. (2006) 216(1):1-10.
   PubMed Web of Science ®Google Scholar
• RICHERT L, LIGUORI MJ, ABADIE C et al.: Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab. Dispos. (2006) 34(5):870-879.
   PubMed Web of Science ®Google Scholar
• KIER LD, NEFT R, TANG L et al.: Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague–Dawley rats in vivo and human hepatocytes in vitro. Mutat. Res. (2004) 549(1-2):101-113.
   PubMed Web of Science ®Google Scholar
• SPIGSET O, HAGG S, BATE A: Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int. Clin. Psychopharmacol. (2003) 18(3):157-161.
   PubMed Web of Science ®Google Scholar
• KOSTRUBSKY SE, STROM SC, KALGUTKAR AS et al.: Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. (2006) 90(2):451-459.
   PubMed Web of Science ®Google Scholar
• KOSTRUBSKY VE, STROM SC, HANSON J et al.: Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol. Sci. (2003) 76(1):220-228.
   PubMed Web of Science ®Google Scholar
• KALGUTKAR AS, VAZ AD, LAME ME et al.: Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab. Dispos. (2005) 33(2):243-253.
   PubMed Web of Science ®Google Scholar
• DAMBACH DM, ANDREWS BA, MOULIN F: New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. (2005) 33(1):17-26.
   PubMed Web of Science ®Google Scholar
• GAO J, ANN GARULACAN L, STORM SM et al.: Identification of in vitro protein biomarkers of idiosyncratic liver toxicity. Toxicol In Vitro (2004) 18(4):533-541.
   PubMed Web of Science ®Google Scholar